GIP + GLP-1 refers to a new generation of weight-loss medications that combine two powerful gut-derived hormones: Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1)
The SURMOUNT clinical trial program is the largest body of evidence for tirzepatide weight loss, and the results are specific enough to set realistic expectations at each dose level
Importantly, results also demonstrated that the enhancement effect of LASSS on the c-met binding-affinity of HGF is consistently maintained, even after the removal of un-reacted free LASSS (and any degradation products of LASSS), by an interaction between HGF and LASSS or potentially by specific chemical modification of HGF at a high molar ratio of 1:8000 to HGF (over 1:4000)
People with a history of pancreatitis should use caution
Has a mild to moderate pocket of arm fat that resists diet and exercise
Do not start, change, increase, decrease or discontinue your medications without consulting with your physician